Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/168023
Full metadata record
DC FieldValueLanguage
dc.contributor.authorRapado González, Óscar-
dc.contributor.authorMajem, Blanca-
dc.contributor.authorÁlvarez Castro, Ana-
dc.contributor.authorDíaz Peña, Roberto-
dc.contributor.authorAbalo, Alicia-
dc.contributor.authorSuárez Cabrera, Leticia-
dc.contributor.authorGil Moreno, Antonio-
dc.contributor.authorSantamaría, Anna-
dc.contributor.authorLópez López, Rafael-
dc.contributor.authorMuinelo Romay, Laura-
dc.contributor.authorSuarez Cunqueiro, María Mercedes-
dc.date.accessioned2020-07-07T15:30:50Z-
dc.date.available2020-07-07T15:30:50Z-
dc.date.issued2019-12-01-
dc.identifier.urihttp://hdl.handle.net/2445/168023-
dc.description.abstractSalivary microRNAs (miRNAs) are of high interest as diagnostic biomarkers for non-oral cancer. However, little is known about their value for colorectal cancer (CRC) detection. Our study aims to characterize salivary miRNAs in order to identify non-invasive markers for CRC diagnosis. The screening of 754 miRNAs was performed in saliva samples from 14 CRC and 10 healthy controls. The differential expressed miRNAs were validated by RT-qPCR in 51 CRC, 19 adenomas and 37 healthy controls. Receiver operating characteristic (ROC) curves and logistic regression models were performed to analyze the clinical value of these miRNAs. Twenty-two salivary miRNAs were significantly deregulated in CRC patients vs. healthy individuals (p < 0.05) in the discovery phase. From those, five upregulated miRNAs (miR-186-5p, miR-29a-3p, miR-29c-3p, miR-766-3p, and miR-491-5p) were confirmed to be significantly higher in the CRC vs. healthy group (p < 0.05). This five-miRNA signature showed diagnostic value (72% sensitivity, 66.67% specificity, AUC = 0.754) to detect CRC, which was even higher in combination with carcinoembryonic antigen (CEA) levels. Overall, after the first global characterization of salivary miRNAs in CRC, a five-miRNA panel was identified as a promising tool to diagnose this malignancy, representing a novel approach to detect cancer-associated epigenetic alterations using a non-invasive strategy.-
dc.format.extent13 p.-
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherMdpi-
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.3390/jcm8122029-
dc.relation.ispartofJournal Of Clinical Medicine, 2019-12-01, Vol. 8, Issue 12-
dc.relation.urihttps://doi.org/10.3390/jcm8122029-
dc.rightscc by (c) Rapado González, Óscar et al.,2019-
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.sourceArticles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))-
dc.subject.classificationCàncer colorectal-
dc.subject.classificationMarcadors bioquímics-
dc.subject.otherColorectal cancer-
dc.subject.otherBiochemical markers-
dc.titleA Novel Saliva-Based miRNA Signature for Colorectal Cancer Diagnosis-
dc.typeinfo:eu-repo/semantics/article-
dc.typeinfo:eu-repo/semantics/publishedVersion-
dc.date.updated2020-07-06T08:26:35Z-
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess-
dc.identifier.pmid31757017-
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
Rapado-GonzalezO.pdf2.2 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons